Treatment with bortezomib in dense deposit disease associated with monoclonal gammopathy of undetermined significance Recent reviews describe the association between dense deposit disease (DDD) and monoclonal gammopathy of undetermined significance (MGUS), which could play an important role in dysregulation of the alternative complement pathway (ACP) (Sethi & Rajkumar, 2013). Here we report a case of DDD associated with MGUS, with progressive impairment of kidney function and nephrotic range proteinuria. As the treatment of DDD is based upon the underlying aetiology, we considered starting chemotherapy with bortezomib.The patient, a 54-year-old man with no medical history, was referred for assessment of kidney insufficiency discovered 3 months earlier. On physical examination, no abnormalities except for hypertension (190/100 mmHg) were found. Laboratory analysis showed: serum creatinine 257Á2 lmol/l; estimated glomerular filtration rate (eGFR) 23 ml/min/1Á73 m 2 ,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.